Karlijn P M Suijkerbuijk

46PUBLICATIONS
143CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Epidemiological modelling
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (46)

|Oct 01, 2026
Five-year survival with neoadjuvant therapy in melanoma: updated pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC).

|Jun 26, 2026
Age-Stratified Long-Term Outcomes of Immune Checkpoint Inhibitors for Stage IV Melanoma and NSCLC in The Netherlands: A Population-Based Study.

|May 04, 2026
Discontinuation of combo immunotherapy and outcome of patients with melanoma brain metastases.

|Jan 28, 2026
Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO-trial.

Lotte L Hoeijmakers, Petros Dimitriadis, Steven C M A Wijnen

|Nov 18, 2025
Blood and tissue correlates of steroid non-response in checkpoint inhibition-induced immune-related adverse events.

Mick J M van Eijs, M Marlot van der Wal, Hedi-Britt Klotškova

|Sep 02, 2025
Anti-PD-1 treatment response is associated with the influx of circulating myeloid and T-cell subsets into the metastatic melanoma tumor microenvironment.

S Van Dam, D Krijgsman, E Küçükköse

Pageof 8

Frequent Collaborators

18 joint publications

Ellen W Kapiteijn

14 joint publications

Michel W Wouters

11 joint publications

Rik J Verheijden

9 joint publications

Astrid Van der Veldt